Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Price, Quote, News and Overview

NASDAQ:CAPR - Nasdaq - US14070B3096 - Common Stock - Currency: USD

10.48  +0.23 (+2.24%)

After market: 10.5 +0.02 (+0.19%)

CAPR Quote, Performance and Key Statistics

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (5/27/2025, 8:05:51 PM)

After market: 10.5 +0.02 (+0.19%)

10.48

+0.23 (+2.24%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High23.4
52 Week Low3.52
Market Cap479.04M
Shares45.71M
Float38.03M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-05 2025-08-05
IPO06-04 2002-06-04


CAPR short term performance overview.The bars show the price performance of CAPR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

CAPR long term performance overview.The bars show the price performance of CAPR in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of CAPR is 10.48 USD. In the past month the price decreased by -18.32%. In the past year, price increased by 84.51%.

CAPRICOR THERAPEUTICS INC / CAPR Daily stock chart

CAPR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About CAPR

Company Profile

CAPR logo image Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in San Diego, California and currently employs 160 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Company Info

CAPRICOR THERAPEUTICS INC

10865 Road to the Cure, Suite 150

San Diego CALIFORNIA 90211 US

CEO: Linda Marban

Employees: 160

CAPR Company Website

CAPR Investor Relations

Phone: 18587271755

CAPRICOR THERAPEUTICS INC / CAPR FAQ

What is the stock price of CAPRICOR THERAPEUTICS INC today?

The current stock price of CAPR is 10.48 USD. The price increased by 2.24% in the last trading session.


What is the ticker symbol for CAPRICOR THERAPEUTICS INC stock?

The exchange symbol of CAPRICOR THERAPEUTICS INC is CAPR and it is listed on the Nasdaq exchange.


On which exchange is CAPR stock listed?

CAPR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CAPRICOR THERAPEUTICS INC stock?

13 analysts have analysed CAPR and the average price target is 44.59 USD. This implies a price increase of 325.46% is expected in the next year compared to the current price of 10.48. Check the CAPRICOR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CAPRICOR THERAPEUTICS INC worth?

CAPRICOR THERAPEUTICS INC (CAPR) has a market capitalization of 479.04M USD. This makes CAPR a Small Cap stock.


How many employees does CAPRICOR THERAPEUTICS INC have?

CAPRICOR THERAPEUTICS INC (CAPR) currently has 160 employees.


What are the support and resistance levels for CAPRICOR THERAPEUTICS INC (CAPR) stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a support level at 10.24 and a resistance level at 10.49. Check the full technical report for a detailed analysis of CAPR support and resistance levels.


Is CAPRICOR THERAPEUTICS INC (CAPR) expected to grow?

The Revenue of CAPRICOR THERAPEUTICS INC (CAPR) is expected to grow by 132.64% in the next year. Check the estimates tab for more information on the CAPR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CAPRICOR THERAPEUTICS INC (CAPR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CAPRICOR THERAPEUTICS INC (CAPR) stock pay dividends?

CAPR does not pay a dividend.


When does CAPRICOR THERAPEUTICS INC (CAPR) report earnings?

CAPRICOR THERAPEUTICS INC (CAPR) will report earnings on 2025-08-05.


What is the Price/Earnings (PE) ratio of CAPRICOR THERAPEUTICS INC (CAPR)?

CAPRICOR THERAPEUTICS INC (CAPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).


What is the Short Interest ratio of CAPRICOR THERAPEUTICS INC (CAPR) stock?

The outstanding short interest for CAPRICOR THERAPEUTICS INC (CAPR) is 27.21% of its float. Check the ownership tab for more information on the CAPR short interest.


CAPR Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR is one of the better performing stocks in the market, outperforming 90.77% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CAPR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CAPR. While CAPR seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CAPR Financial Highlights

Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -63.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.81%
ROE -43.14%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-70.97%
Sales Q2Q%-100%
EPS 1Y (TTM)-63.22%
Revenue 1Y (TTM)-35.94%

CAPR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to CAPR. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 59.37% and a revenue growth 132.64% for CAPR


Ownership
Inst Owners38.5%
Ins Owners1.16%
Short Float %27.21%
Short Ratio5.42
Analysts
Analysts84.62
Price Target44.59 (325.48%)
EPS Next Y59.37%
Revenue Next Year132.64%